Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9

Wang,Qi; Tang,Huihuan; Yin,Shanshan; Dong,Chao

doi:10.3892/or.2013.2304

Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9

Authors:
- Qi Wang
- Huihuan Tang
- Shanshan Yin
- Chao Dong
View Affiliations

Affiliations: Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: February 26, 2013 https://doi.org/10.3892/or.2013.2304
Pages: 2046-2052

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRs) play an important role in tumor initiation and progression in many types of cancer, including cholangiocarcinoma (CC). miR-138 dysregulation is frequently observed in a variety of tumors. In the present study, miR-138 was found to be downregulated in CC tissues by quantitative real-time RT-PCR. Furthermore, its potential target molecule, Ras homolog gene family, member C (RhoC) protein, was found to be highly expressed in CC tissues examined by western blot analysis. Luciferase reporter assay further demonstrated that miR-138 directly targeted RhoC. We found that the introduction of miR-138 mimics to RBE and QBC939 CC cells could reduced RhoC mRNA and protein expression, and suppressed the proliferation, G1/S transition, migration and invasion of CC cells. However, transfection with a miR-138 inhibitor induced an inverse effect in CC cells. The expression of phosphorylated extracellular signal-regulated kinase (p-ERK), matrix metalloproteinase (MMP)-2 and MMP-9 decreased following transfection with miR-138, and increased following transfection with miR-138 inhibitor in CC cells. In conclusion, RhoC upregulation induced by miR-138 downregulation promotes the malignant progression of CC cells and the underlying mechanisms of this effect involve the increase in the expression of p-ERK/MMP-2/MMP-9. Consequently, miR-138/RhoC is a potential target for the clinical diagnosis and treatment of CC.

View Figures

View References

1	Shimoda M and Kubota K: Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol. 13:1500–1504. 2007. View Article : Google Scholar : PubMed/NCBI
2	Patel T: Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar
3	Reddy SB and Patel T: Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 8:30–37. 2006. View Article : Google Scholar : PubMed/NCBI
4	Singh P and Patel T: Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol. 22:294–299. 2006. View Article : Google Scholar
5	Kawahigashi Y, Mishima T, Mizuguchi Y, et al: MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nippon Med Sch. 76:188–197. 2009. View Article : Google Scholar : PubMed/NCBI
6	Isomoto H: Epigenetic alterations associated with cholangiocarcinoma (Review). Oncol Rep. 22:227–232. 2009.PubMed/NCBI
7	Chen L, Yan HX, Yang W, et al: The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 50:358–369. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhong XY, Yu JH, Zhang WG, et al: MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene. 493:44–51. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhang J, Han C and Wu T: MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology. 143:246–256.e248. 2012.PubMed/NCBI
10	Yamanaka S, Campbell NR, An F, et al: Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle. 11:2729–2738. 2012. View Article : Google Scholar : PubMed/NCBI
11	Razumilava N, Bronk SF, Smoot RL, et al: miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology. 55:465–475. 2012. View Article : Google Scholar : PubMed/NCBI
12	Oishi N, Kumar MR, Roessler S, et al: Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 56:1792–1803. 2012. View Article : Google Scholar
13	Liu CZ, Liu W, Zheng Y, et al: PTEN and PDCD4 are bona fide targets of microRNA-21 in human cholangiocarcinoma. Chin Med Sci J. 27:65–72. 2012.PubMed/NCBI
14	He Q, Cai L, Shuai L, et al: Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing MicroRNA-21. Mol Carcinog. Dec 28–2011.(Epub ahead of print).
15	Selaru FM, Olaru AV, Kan T, et al: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI
16	Li B, Han Q, Zhu Y, Yu Y, Wang J and Jiang X: Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 279:2393–2398. 2012. View Article : Google Scholar : PubMed/NCBI
17	Chen YJ, Luo J, Yang GY, Yang K, Wen SQ and Zou SQ: Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. World J Gastroenterol. 18:3849–3861. 2012. View Article : Google Scholar : PubMed/NCBI
18	Chen Y, Luo J, Tian R, Sun H and Zou S: miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci. 56:1693–1701. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chen Y, Gao W, Luo J, Tian R, Sun H and Zou S: Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Oncol Rep. 25:443–451. 2011. View Article : Google Scholar : PubMed/NCBI
20	Olaru AV, Ghiaur G, Yamanaka S, et al: MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology. 54:2089–2098. 2011. View Article : Google Scholar : PubMed/NCBI
21	Meng F, Wehbe-Janek H, Henson R, Smith H and Patel T: Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 27:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
22	Lee ST, Chu K, Im WS, et al: Altered microRNA regulation in Huntington’s disease models. Exp Neurol. 227:172–179. 2011.
23	Jiang L, Liu X, Kolokythas A, et al: Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer. 127:505–512. 2010. View Article : Google Scholar : PubMed/NCBI
24	Liu X, Chen Z, Yu J, Xia J and Zhou X: MicroRNA profiling and head and neck cancer. Comp Funct Genomics. 2009:8375142009.PubMed/NCBI
25	Mitomo S, Maesawa C, Ogasawara S, et al: Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci. 99:280–286. 2008. View Article : Google Scholar : PubMed/NCBI
26	Poliseno L, Haimovic A, Segura MF, et al: Histology-specific microRNA alterations in melanoma. J Invest Dermatol. 132:1860–1868. 2012. View Article : Google Scholar : PubMed/NCBI
27	Jiang L, Dai Y, Liu X, et al: Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. Hum Genet. 129:189–197. 2011. View Article : Google Scholar : PubMed/NCBI
28	Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012. View Article : Google Scholar : PubMed/NCBI
29	Liu X, Lv XB, Wang XP, et al: MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle. 11:2495–2506. 2012. View Article : Google Scholar : PubMed/NCBI
30	Clark EA, Golub TR, Lander ES and Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 406:532–535. 2000. View Article : Google Scholar : PubMed/NCBI
31	Iiizumi M, Bandyopadhyay S, Pai SK, et al: RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res. 68:7613–7620. 2008. View Article : Google Scholar : PubMed/NCBI
32	Shi Z, Chen ML, He QL and Zeng JH: Antisense RhoC gene suppresses proliferation and invasion capacity of human QBC939 cholangiocarcinoma cells. Hepatobiliary Pancreat Dis Int. 6:516–520. 2007.PubMed/NCBI
33	Arocho A, Chen B, Ladanyi M and Pan Q: Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn Mol Pathol. 15:56–61. 2006.PubMed/NCBI
34	Saadoun S, Papadopoulos MC, Hara-Chikuma M and Verkman AS: Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature. 434:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
35	Aspenstrom P, Fransson A and Saras J: Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J. 377:327–337. 2004. View Article : Google Scholar : PubMed/NCBI
36	Ravenhall C, Guida E, Harris T, Koutsoubos V and Stewart A: The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle. Br J Pharmacol. 131:17–28. 2000. View Article : Google Scholar : PubMed/NCBI
37	Corona G, Deiana M, Incani A, Vauzour D, Dessi MA and Spencer JP: Hydroxytyrosol inhibits the proliferation of human colon adenocarcinoma cells through inhibition of ERK1/2 and cyclin D1. Mol Nutr Food Res. 53:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
38	Ikoma T, Takahashi T, Nagano S, et al: A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res. 10:1192–1200. 2004. View Article : Google Scholar : PubMed/NCBI
39	Xue F, Takahara T, Yata Y, et al: Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res. 38:810–817. 2008. View Article : Google Scholar
40	van Golen KL, Wu ZF, Qiao XT, Bao LW and Merajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 60:5832–5838. 2000.
41	Blain EJ: Mechanical regulation of matrix metalloproteinases. Front Biosci. 12:507–527. 2007. View Article : Google Scholar : PubMed/NCBI
42	Ehrenfeld P, Conejeros I, Pavicic MF, et al: Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. Cancer Lett. 301:106–118. 2011. View Article : Google Scholar : PubMed/NCBI
43	Ming J, Liu N, Gu Y, Qiu X and Wang EH: PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology. 41:118–126. 2009. View Article : Google Scholar : PubMed/NCBI